Strategic partnerships AffaMed has active and historical licensing and collaboration deals with multiple ophthalmology and neuroscience players (Ocular Therapeutix, VistaGen, Allgenesis, IBT). This indicates a mature BD approach and a ready-made playbook for co-development, regional commercialization, and technology licensing opportunities in Greater China, South Korea, ASEAN, and ASEAN markets.

Regional expansion focus The company emphasizes Greater China and ASEAN markets for key products like DEXTENZA and AG-73305, suggesting sales opportunities by aligning with local healthcare providers, distributors, and payer strategies in these regions, supported by a physician-administered sustained-release product model.

Digital therapeutics edge AffaMed is pursuing novel digital therapies (DTx) in collaboration with Beijing Tiantan Hospital and IBT, presenting a cross-sale angle to healthcare systems seeking integrated CNS solutions, data and remote monitoring capabilities, and potential government or academic partnership programs.

Diversified product portfolio The portfolio spans ophthalmic implants (EXTENS?) and IOLs, eye disease therapeutics, and neurology/psychiatry, offering multiple entry points for sales teams targeting ophthalmology clinics, hospital networks, and specialty CNS centers with reciprocal cross-selling.

Strong financial base With revenue in the tens of millions and substantial funding, AffaMed has financial backing to pursue licensing, co-development, and regional commercialization activities, enabling BD teams to proposal-pack financing scenarios and milestone-based partnerships.